Home » Business News » 2012 » December » December 13, 2012

GeoVax Labs Featured in Five Publications

December 13, 2012 - ATLANTA, GA

GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, was featured in five publications during the past two weeks, a period also marked by the observance of World AIDS Day 2012 on December 1.

On November 23, The Atlanta Journal-Constitution published David Markiewicz's article "Small Smyrna biotech firm GeoVax looking for big impact with HIV vaccine" that profiles GeoVax's HIV vaccine programs. To read the article, please visit:

Also on November 23, The Georgia Voice published Matt Schafer's article "HIV vaccine studies show promising results" that spotlights the vaccine created by GeoVax's CSO Harriet L. Robinson, Ph.D., as a key potential tool in the HIV/AIDS battle. To read the article, please visit:

On November 30, METRO New York published Meredith Engel's profile "Dr. Bob McNally: Meet the man behind a promising HIV vaccine" that offers a Q&A with GeoVax's President and CEO. To read the article, please visit:

On December 4, Genetic Engineering & Biotechnology News (GEN) published an article by Dr. McNally, "HIV-AIDS Vaccines: Where Are We Now and Where Are We Heading?" that highlights reasons for optimism within the HIV research community. To read the article, please visit:

Finally, the December issue of Life Science Leader included Clifford Mintz, Ph.D.'s article "HIV/AIDS Vaccine Development: Are We Any Closer?" that emphasizes the need for HIV/AIDS vaccines, discusses the recent momentum in the industry, and notes that GeoVax is the only commercial entity with a leading Phase 2 vaccine. To read the article, please visit: The article appears on pages 32-33.

About GeoVax Labs
GeoVax Labs is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability toraise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported testing in a Phase 2a trial that was completed in the 3rd quarter of 2012. The 2nd generation of its preventive vaccine is in phase 1 testing and planned to progress to a multi-stage Phase 2 efficacy study, given that safety and immunogenicity are as expected. Overall, the GeoVax vaccine, in various doses and combinations, has been tested in close to 500 human subjects. GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit

Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Dian Griesel Inc.
Dillon Heins
Investor Relations
Susan Forman or Laura Radocaj
Public Relations
(212) 825-3210


Comment on this story